— Know what they know.
Not Investment Advice

ELVN Short Interest

Enliven Therapeutics, Inc.
1W: +7.2% 1M: -7.3% 3M: -22.8% YTD: +167.0% 1Y: +101.9% 3Y: +226.9% 5Y: +175.9%
$43.69
+2.20 (+5.30%)
After Hours: $43.28 (-0.41, -0.93%)
Weekly Expected Move ±6.8%
$36 $39 $42 $44 $47
NASDAQ · Healthcare · Biotechnology · Tech Score Neutral · Power 41 · $3.0B mcap · 47M float · 2.86% daily turnover · Short 78% of daily vol
Credit Risk of going bust: lower than 83% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Enliven Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $3.04B.
Distance to default 10.59 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.1M (short-term plus half of long-term), stock volatility 73.1%; Altman Z'' 66.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Short Volume Summary

2026-10-26
76.0%
Short Ratio
of total volume
61.8%
20-Day Avg
58.8%
50-Day Avg
▲ Rising
5-Day Trend
0.4M
Short Volume
0.5M
Total Volume

Daily Short Volume Ratio

Short Volume vs Total Volume

Exchange Breakdown

2026-10-26
ExchangeShort VolumeTotal VolumeShort %
NASDAQ 311,246 412,651 75.4%
NYSE 39,146 48,613 80.5%
BATS 440 591 74.5%

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms